STOCK TITAN

Jade Biosciences Q3 net loss widens to $35.1M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Jade Biosciences, Inc. (JBIO) reported a third-quarter 2026 net loss of $35.055 million, compared with $25.175 million a year earlier. Operating expenses were $39.640 million, versus $27.401 million, and net loss per common share was $0.42 versus $0.48. Cash, cash equivalents and investments totaled $475.706 million as of September 30, 2026, compared with $336.158 million as of December 31, 2025.

Jade said it is preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule and expects to advance JADE301 into the clinic this quarter. The company expects JADE101, JADE201 and JADE301 to be three clinical-stage programs heading into 2027. Nine-month net loss was $131.188 million, compared with $95.478 million for the same period in 2025.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointNet loss per common share narrowed to $0.42 from $0.48.

Negative

  • Moderate pointThird-quarter net loss rose to $35.055 million from $25.175 million.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Net loss $35.055 million Three months ended September 30, 2026; $25.175 million in the year-earlier quarter
Operating expenses $39.640 million Three months ended September 30, 2026; $27.401 million in the year-earlier quarter
Cash, cash equivalents and investments $475.706 million As of September 30, 2026; $336.158 million as of December 31, 2025
Research and development expense $30.823 million Three months ended September 30, 2026; $22.010 million in Q3 2025
Net loss per common share ($0.42) Three months ended September 30, 2026; ($0.48) in Q3 2025
Nine-month net loss $131.188 million Nine months ended September 30, 2026; $95.478 million in the same 2025 period
IgA nephropathy (IgAN) medical
"for IgA nephropathy (IgAN)"
IgA nephropathy is a kidney disease caused by immune proteins (IgA antibodies) depositing in the kidney’s filters, leading over time to blood and protein leaking into the urine and gradual loss of kidney function. It matters to investors because its chronic nature creates demand for diagnostics, long-term therapies and clinical trials; trial results, regulatory approvals, or new treatments can materially affect companies focused on kidney disease much like a new product can reshape a market.
anti-APRIL monoclonal antibody medical
"JADE101: anti-APRIL monoclonal antibody"
afucosylated technical
"an afucosylated anti-BAFF-R monoclonal antibody"
Afucosylated describes a biologic drug—usually an antibody—that has had a specific sugar molecule (fucose) removed from its tail region, which changes how well immune cells can grab and destroy targeted cells. Removing that sugar is like replacing a weak magnet with a stronger one: it often boosts the drug’s ability to recruit immune attack, potentially making it more potent, allowing lower doses or clearer clinical advantages, but also adding manufacturing and regulatory considerations investors should watch.
anti-BAFF-R monoclonal antibody medical
"JADE201: anti-BAFF-R monoclonal antibody"
registrational study regulatory
"trial will serve as a registrational study"
A registrational study is a late-stage clinical trial designed to give the government regulators the evidence they need to decide whether a drug, therapy, or medical device can be approved for sale. Think of it as the final exam or road test for a medical product: its results largely determine whether the product can reach the market, which directly affects potential revenue, company valuation, and investor risk.
interim data medical
"availability of interim data from the Phase 2 clinical trial"
Information collected and analyzed from an ongoing study, trial, or financial period before the project is finished. Interim data is like a mid-race snapshot that shows how things are progressing — it can reveal early signs of safety, effectiveness, or performance but is provisional and may change as more data come in, so it often influences investor expectations and market reactions.
Net loss, three months $35.055 million Compared with $25.175 million in the year-earlier quarter
Operating expenses, three months $39.640 million Compared with $27.401 million in the year-earlier quarter
Research and development expense, three months $30.823 million Compared with $22.010 million in Q3 2025
Net loss per common share, three months ($0.42) Compared with ($0.48) in Q3 2025
Net loss, nine months $131.188 million Compared with $95.478 million in the same 2025 period
Cash, cash equivalents and investments $475.706 million Compared with $336.158 million as of December 31, 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was Jade Biosciences' net loss in Q3 2026?

Jade reported a net loss of $35.055 million for the three months ended September 30, 2026, compared with $25.175 million in the year-earlier quarter.

How much did JBIO spend on research and development in Q3 2026?

Jade reported $30.823 million in research and development expense for the three months ended September 30, 2026, compared with $22.010 million in Q3 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
NASDAQ false 0001798749 0001798749 2026-11-13 2026-11-13
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

 

 

Jade Biosciences, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Nevada   001-40544   83-1377888
(State or other jurisdiction
of incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

221 Crescent St., Building 23

Suite 105
Waltham, MA

  02453
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (781) 312-3013

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   JBIO   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 
 


Item 2.02. Results of Operations and Financial Condition.

On November 13, 2026, Jade Biosciences, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).

This Item 2.02 and Exhibit 99.1 to this Report are being furnished to the SEC and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT INDEX

 

Exhibit   

Description

99.1    Press release issued on November 13, 2026.
104    Cover page interactive data file (embedded within the inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Jade Biosciences, Inc.
    (Registrant)
Date: November 13, 2026     By:  

/s/ Bradford Dahms

    Name:   Bradford Dahms
    Title:   Chief Financial Officer and Chief Business Officer

Exhibit 99.1

Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

 

  •  

JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026

 

  •  

JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027

 

  •  

JADE201 Phase 1 clinical trial in rheumatoid arthritis ongoing; interim data expected in 2027

 

  •  

JADE301 Phase 1 clinical trial in dermatomyositis expected to initiate in the fourth quarter of 2026, with interim data expected in the second half of 2027

 

  •  

Cash, cash equivalents, and investments of $476 million as of September 30, 2026 expected to provide runway into the fourth quarter of 2028

San Francisco and Vancouver, British Columbia – November 13, 2026 – Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the third quarter ending September 30, 2026, and provided a corporate update.

“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones,” said Tom Frohlich, Chief Executive Officer of Jade. “We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile. We also expect to advance JADE301 into the clinic this quarter, which, alongside JADE101 and JADE201, will give us three clinical-stage programs heading into 2027. With multiple clinical catalysts expected across our pipeline next year, we see significant opportunities to further demonstrate the differentiated profiles of our programs and ultimately deliver meaningful new therapies for patients with autoimmune disease.”

Pipeline and Corporate Updates

JADE101: anti-APRIL monoclonal antibody for IgA nephropathy (IgAN)

 

  •  

Jade expects to initiate EVERGREEN, a Phase 3 registrational trial of JADE101 in IgAN, in the fourth quarter of 2026, reflecting the Company’s rapid execution as JADE101 advances into registrational development. A Trial-in-Progress poster describing EVERGREEN was presented at the American Society of Nephrology (ASN) Kidney Week 2026.

 

  •  

Enrollment in the Phase 2 JUNIPER trial of JADE101 in IgAN is ongoing, with interim data expected in the second quarter of 2027. A Trial-in-Progress poster describing JUNIPER was presented at ASN Kidney Week 2026.

JADE201: anti-BAFF-R monoclonal antibody for autoimmune diseases

 

  •  

The Phase 1 clinical trial evaluating JADE201 in participants with rheumatoid arthritis is ongoing, with interim biomarker-rich data expected in 2027 to inform indication prioritization.


JADE301: anti-IFN-b monoclonal antibody for dermatomyositis

 

  •  

Jade presented preclinical data at the 2026 European Academy of Dermatology and Venereology (EADV) Congress supporting the potentially differentiated profile of JADE301 in dermatomyositis. Key results included:

 

  •  

JADE301 demonstrated selective, high-affinity binding to IFN-β and greater functional potency than a dazukibart comparator in disease-relevant human cells.

 

  •  

Following subcutaneous (SC) administration in non-human primates, JADE301 demonstrated an approximately 25-day half-life and was well tolerated at all dose levels evaluated, supporting the potential for infrequent SC dosing.

 

  •  

Jade expects to initiate a Phase 1 trial of JADE301 in healthy volunteers in the fourth quarter of 2026, with interim data anticipated in the second half of 2027.

Corporate

 

  •  

Expanded Brad Dahms’ role and title to Chief Financial Officer and Chief Business Officer. Mr. Dahms will continue to oversee the Company’s finance and investor relations functions and will now also lead business development and corporate strategy as Jade advances its pipeline toward multiple clinical readouts in 2027.

Third Quarter 2026 Financial Results

 

  •  

Cash Position: As of September 30, 2026, Jade had cash, cash equivalents, and investments of $475.7 million. Based on its current operating plans, Jade believes that its existing cash, cash equivalents and investments will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2028.

 

  •  

Research and Development (R&D) expenses: R&D expenses were $30.8 million for the third quarter ended September 30, 2026, an increase of $8.8 million compared to the third quarter of 2025, and included $3.6 million in stock-based compensation expense. R&D expenses increased primarily due to increased costs around chemistry, manufacturing and controls, clinical activity, and personnel-related costs and related stock-based compensation expense.

 

  •  

General and Administrative (G&A) expenses: G&A expenses were $8.8 million for the third quarter ended September 30, 2026, an increase of $3.4 million compared to the third quarter of 2025, and included $3.5 million in stock-based compensation expense. The increase in G&A expenses was primarily due to higher personnel-related costs and related stock-based compensation expense.

 

  •  

Net loss: Net loss totaled $35.1 million for the third quarter ended September 30, 2026, compared to $25.2 million for the third quarter of 2025. Net loss increased primarily due to higher R&D and G&A expenses, as described above.

 

Page 2


About Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-b monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation: Jade’s ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and JADE301 and their best-in-class potential; Jade’s plans to conduct a Phase 3 clinical trial of JADE101, the design and timing thereof and Jade’s expectations that such trial will serve as a registrational study; the expected timelines for the initiation of the Phase 1 clinical trial of JADE301 and for the availability of interim data from the Phase 2 clinical trial of JADE101 and the Phase 1 clinical trials of JADE201 and JADE301; expectations regarding the type of data anticipated to be received from the Phase 1 clinical trial of JADE201; the potential therapeutic uses, efficacy, durability, safety profiles, and dosing of JADE101, JADE201 and JADE301; and the potential for Jade’s cash, cash equivalents and investments to provide runway into the fourth quarter of 2028. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: interim results of a clinical trial are not necessarily indicative of final results and one or more of the outcomes may materially change following more comprehensive reviews of the data, as follow-up on the outcome of any particular participant continues and as more participant or final data becomes available; predicted data for JADE101 may not be realized in actual clinical studies; the ongoing and planned clinical trials of JADE101, JADE201 and JADE301 and any other clinical trials may be delayed or may not demonstrate desirable efficacy or predicted performance; Jade’s planned JADE101 Phase 3 clinical trial may be delayed based on FDA feedback or requirements, as the FDA retains broad discretion to require additional clinical data for any product candidate prior to the conduct of a Phase 3 clinical trial or submission for regulatory approval; even if such Phase 3 trial is successful, it may not support regulatory approval; adverse events and safety signals may occur; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade’s product candidates may be delayed to a point where they are not commercially viable;

 

Page 3


clinical trial start up, enrollment or regulatory challenges may occur; challenges associated with Jade’s dependence on third-party vendors for the development, manufacture and supply of its product candidates may occur; Jade may use its capital resources sooner than expected; and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.

Jade Biosciences Contact

Zane Goodwin

IR@JadeBiosciences.com

Media@JadeBiosciences.com

 

Page 4


JADE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

 

     September 30,
2026
     December 31,
2025
 

Cash, cash equivalents and investments

   $ 475,706      $ 336,158  

Other assets

     10,685        13,623  
  

 

 

    

 

 

 

Total assets

   $ 486,391      $ 349,781  
  

 

 

    

 

 

 

Total liabilities

   $ 30,887      $ 17,263  
  

 

 

    

 

 

 

Total stockholders’ equity

     455,504        332,518  
  

 

 

    

 

 

 

Total liabilities and stockholders’ equity

   $ 486,391      $ 349,781  
  

 

 

    

 

 

 

 

Page 5


JADE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

 

     Three Months
Ended
September 30,
2026
    Three Months
Ended
September 30,

2025
    Nine Months
Ended
September 30,
2026
    Nine Months
Ended
September 30,

2025
 

Operating expenses

 

Research and development(1)

   $ 30,823     $ 22,010     $ 116,941     $ 64,580  

General and administrative(2)

     8,817       5,391       25,060       13,983  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     39,640       27,401       142,001       78,563  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (39,640 )      (27,401 )      (142,001 )      (78,563 ) 

Other income (expense):

 

Interest income

     4,629       2,254       10,959       4,697  

Change in fair value of Convertible Notes payable(3)

     —        —        —        (21,584 ) 

Other expense

     (34 )      (28 )      (105 )      (28 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expense), net

     4,595       2,226       10,854       (16,915 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss before income tax expense

     (35,045 )      (25,175 )      (131,147 )      (95,478 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Income tax expense

     (10 )      —        (41 )      —   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

     (35,055 )      (25,175 )      (131,188 )      (95,478 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss):

 

Currency translation adjustment

   $ 13     $ 18     $ (58 )    $ (6 ) 

Unrealized gain (loss) on investments

   $ (1,419 )    $ 35     $ (2,137 )    $ 35  
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss

   $ (36,461 )    $ (25,122 )    $ (133,383 )    $ (95,449 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

   $ (0.42 )    $ (0.48 )    $ (1.72 )    $ (3.08 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted

   $ (415.39 )    $ (482.25 )    $ (1,721.52 )    $ (3,081.78 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted

     71,763,164       39,584,489       63,581,599       23,816,586  
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted

     12,622       12,622       12,622       7,166  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

(1)

Includes related party amounts of $0.3 million and $17.6 million for the three and nine months ended September 30, 2026, respectively, and $5.8 million and $17.5 million for the three and nine months ended September 30, 2025, respectively.

(2)

Includes no related party amount for the three months ended September 30, 2026 and $0.2 million for the nine months ended September 30, 2026. Includes related party amounts of $0.2 million for each of the three and nine months ended September 30, 2025.

(3)

Includes $4.6 million for the nine months ended September 30, 2025.

 

Page 6

Filing Exhibits & Attachments

4 documents

Keep reading